Drugs / 68Gallium-PSMA-11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT04377152 | — | prostate adenocarcinoma | University of California, San Francisco | Approved for marketing | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Gallium-PSMA-11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04377152 ↗ |
| Known as | PSMA-11 | “PSMA-11 Ga 68 Injection is a positron emitting radiopharmaceutical containing radioactive 68Ga-labeled Glu-NH-CO-NH-Lys(Ahx)-HBED-CC (PSMA-11), which is used for diagnostic...” NCT04377152 ↗ |
| Modality | Diagnostic / imaging agent | “which is used for diagnostic purposes in conjunction with Positron Emission Tomography (PET)” NCT04377152 ↗ |